Prime Medicine Inc
PRME4.500USD
+0.460+11.38%
交易中 （美东）报价延迟15分钟
590.21M总市值
亏损市盈率 TTM
关于 Prime Medicine Inc 公司
Prime Medicine, Inc. 是一家生物技术公司，致力于为患者创造和提供基因编辑疗法。该公司部署了其基因编辑技术 Prime Editing 平台，以开发一类新型差异化、一次性基因疗法。该公司致力于开发 Prime Editors，作为一种具有变革潜力的新型疗法，以扩大治疗性精准基因药物的应用。该公司已建立了一个多元化的试验性治疗项目组合，这些项目围绕核心重点领域组织，即血液学和免疫学、肝脏、肺、眼部和神经肌肉。其其他重点领域的项目处于临床前开发的早期阶段，包括肝脏项目，如威尔逊氏病和糖原累积症 1b；肺项目，如囊性纤维化；眼部项目，如视紫红质突变引起的视网膜色素变性，以及神经肌肉项目，包括弗里德赖希共济失调和 1 型肌强直营养不良症。
公司简介
公司代码PRME
公司名称Prime Medicine Inc
上市日期Oct 20, 2022
CEODr. Allan Reine, M.D.
员工数量214
证券类型Ordinary Share
年结日Oct 20
公司地址60 First St.
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02141
电话16174650013
网址https://primemedicine.com/
公司代码PRME
上市日期Oct 20, 2022
CEODr. Allan Reine, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
Ms. Hannah Deresiewicz
Ms. Hannah Deresiewicz
Investor Relations
Investor Relations
--
--
Dr. Andrew Anzalone, M.D., Ph.D.
Dr. Andrew Anzalone, M.D., Ph.D.
Co-Founder, Head of Prime Editing Platform
Co-Founder, Head of Prime Editing Platform
--
--
Dr. Thomas J. Cahill, M.D., Ph.D.
Dr. Thomas J. Cahill, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. David Schenkein, M.D.
Dr. David Schenkein, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2022
暂无数据
地区USD
名称
营收
占比
United States
1.45M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月10日 周六
更新时间: 5月10日 周六
持股股东
股东类型
持股股东
持股股东
占比
Liu (David R)
11.97%
ARCH Venture Partners
9.14%
Alphabet, Inc.
8.90%
Newpath Partners LP
3.61%
Gottesdiener (Keith Michael)
2.58%
Other
63.81%
持股股东
持股股东
占比
Liu (David R)
11.97%
ARCH Venture Partners
9.14%
Alphabet, Inc.
8.90%
Newpath Partners LP
3.61%
Gottesdiener (Keith Michael)
2.58%
Other
63.81%
股东类型
持股股东
占比
Venture Capital
22.99%
Investment Advisor
19.66%
Individual Investor
19.20%
Investment Advisor/Hedge Fund
8.25%
Corporation
4.54%
Hedge Fund
3.95%
Research Firm
0.51%
Family Office
0.05%
Bank and Trust
0.04%
Other
20.81%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
270
104.38M
77.61%
-19.33M
2025Q1
282
106.20M
80.90%
-20.25M
2024Q4
272
108.78M
82.93%
-18.95M
2024Q3
253
113.13M
92.43%
-10.21M
2024Q2
247
124.37M
103.99%
+15.29M
2024Q1
226
122.24M
102.62%
+28.30M
2023Q4
206
100.04M
102.85%
+26.61M
2023Q3
169
100.64M
103.49%
+30.08M
2023Q2
156
87.82M
90.36%
+22.34M
2023Q1
141
87.13M
89.71%
+20.94M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Liu (David R)
20.24M
15.42%
+84.00K
+0.42%
Jun 30, 2025
ARCH Venture Partners
15.46M
11.77%
--
--
Nov 12, 2024
Alphabet, Inc.
15.06M
11.47%
--
--
Mar 31, 2025
Newpath Partners LP
6.11M
4.65%
--
--
Dec 31, 2024
Gottesdiener (Keith Michael)
4.36M
3.32%
+250.00K
+6.08%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.14M
3.16%
+165.27K
+4.15%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.93M
2.99%
-147.01K
-3.61%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.75M
2.85%
-54.79K
-1.44%
Mar 31, 2025
The Vanguard Group, Inc.
3.64M
2.77%
-13.97K
-0.38%
Mar 31, 2025
ARK Investment Management LLC
3.10M
2.36%
-2.06M
-39.90%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ARK Genomic Revolution ETF
0.55%
Global X Genomics & Biotechnology ETF
0.4%
AXS Green Alpha ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
ARK Genomic Revolution ETF
占比0.55%
Global X Genomics & Biotechnology ETF
占比0.4%
AXS Green Alpha ETF
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
